| Literature DB >> 27804314 |
Morten Bondo Christensen1, Karen Busk Nørøxe1, Grete Moth1, Peter Vedsted1, Linda Huibers1.
Abstract
OBJECTIVE: General practitioners are the first point of contact in Danish out-of-hours (OOH) primary care. The large number of contacts implies that prescribing behaviour may have considerable impact on health-care expenditures and quality of care. The aim of this study was to examine the prevailing practices for medication prescription in Danish OOH with a particular focus on patient characteristics and contact type. DESIGN ANDEntities:
Keywords: Denmark; after hours; drug prescription; general practice; primary care
Mesh:
Substances:
Year: 2016 PMID: 27804314 PMCID: PMC5217277 DOI: 10.1080/02813432.2016.1248622
Source DB: PubMed Journal: Scand J Prim Health Care ISSN: 0281-3432 Impact factor: 2.581
Distribution of contacts with and without prescription(s) per contact type.
| All contacts | Contacts with at least one prescription | Contacts without prescription | |
|---|---|---|---|
| Contact type | |||
| Telephone consultations | 382,748 (59.4) | 83,785 (21.9) | 298,963 (78.1) |
| Clinic consultations | 180,032 (27.9) | 59,167 (32.9) | 120,865 (67.1) |
| Home visits | 81,997 (12.7) | 11,716 (14.3) | 70,281 (85.7) |
| Total | 644,777 (100.0) | 154,668 (24.0) | 490,109 (76.0) |
Number of contacts with at least one prescription per 100 OOH contacts (PC rate) according to age, gender and contact type.
| All contacts PC rate(95% CI) | Telephone consultations PC rate (95% CI) | Clinic consultations PC rate (95% CI) | Home visits PC rate(95% CI) | ||
|---|---|---|---|---|---|
| Male | 65,817 | 22.6 (22.5–22.8) | 19.3 (19.1–19.5) | 32.6 (32.3–32.9) | 14.5 (14.2–14.9) |
| Female | 88,851 | 25.1 (25.0–25.3) | 23.9 (23.7–24.1) | 33.1 (32.8–33.4) | 14.1 (13.7–14.4) |
| 0–4 years | 26,581 | 21.1 (20.9–21.3) | 17.2 (17.0–17.5) | 29.4 (28.9–29.8) | 14.0 (13.0–15.0) |
| 5–13 years | 13,212 | 20.9 (20.6–21.2) | 15.6 (15.2–16.0) | 29.5 (28.9–30.1) | 13.7 (12.4–15.1) |
| 14–17 years | 5728 | 21.6 (21.1–22.1) | 18.5 (17.9–19.1) | 27.9 (27.0–28.8) | 12.2 (10.7–13.9) |
| 18–40 years | 53,996 | 27.6 (27.4–27.8) | 25.9 (25.6–26.1) | 34.8 (34.4–35.2) | 12.3 (11.7–12.8) |
| 41–60 years | 31,846 | 27.7 (27.4–27.9) | 26.7 (26.4–27.0) | 37.5 (36.9–40.0) | 12.9 (12.4–13.4) |
| 61–75 years | 13,304 | 21.9 (21.6–22.2) | 20.1 (19.6–20.5) | 35.3 (34.5–36.2) | 13.3 (12.8–13.8) |
| >75 years | 10,001 | 17.4 (17.1–17.7) | 17.8 (17.4–18.3) | 29.5 (27.9–31.1) | 15.5 (15.1–16.0) |
| Total | 154,668 | 24.0 (23.9–24.1) | 21.9 (21.8–22.0) | 32.9 (32.6–33.1) | 14.3 (14.0–14.5) |
PC rate: number of contacts with at least one prescription per 100 contacts.
p for rate between gender for all contacts and telephone consultations <0.01 and for clinic consultations and home visit <0.05.
All prescriptions in the 1-year study period presented with 1st, 2nd and 3rd ATC code level per contact type.
| ATC code level | Telephone consultations | Clinic consultations | Home visits | All | |||
|---|---|---|---|---|---|---|---|
| 1st | 2nd | 3rd | |||||
| J | Anti-infectives for systemic use | 26,679 (29.7) | 41,042 (63.1) | 8676 (65.6) | 76,397 (45.5) | ||
| J01 | Antibacterials | 24,286 | 40,261 | 8,556 | 73,103 | ||
| J05 | Antivirals ( | 1005 | 607 | 87 | 1699 | ||
| J02 | Antimycotics (s | 1369 | 172 | 31 | 1572 | ||
| Rest | J06, J07 | 19 | 2 | 2 | 23 | ||
| S | Sensory organs | 16,058 (17.9) | 5722 (8.8) | 360 (2.7) | 22,140 (13.2) | ||
| S01 | Ophtalmologicals | 15,071 | 3982 | 286 | 19,339 | ||
| S02 | Otologicals | 807 | 1165 | 42 | 2014 | ||
| Rest | S03 | 180 | 575 | 32 | 787 | ||
| Nervous system | 11,247 (12.6) | 2457 (3.8) | 1120 (8.5) | 14,824 (8.8) | |||
| N02 | Analgetics | 6148 | 2058 | 829 | 9035 | ||
| N06 | Psychoanaleptics | 2460 | 75 | 33 | 2568 | ||
| N05 | Psycholeptics | 1381 | 224 | 214 | 1819 | ||
| N03 | N03A | Antiepileptics | 924 | 33 | 13 | 970 | |
| Rest | N01, N04, N07 | 334 | 67 | 64 | 432 | ||
| R | Respiratory system | 8850 (9.9) | 4947 (7.6) | 624 (4.7) | 14,421 (8.6) | ||
| R03 | Drugs for obstructive airway diseases | 4339 | 2493 | 418 | 7250 | ||
| R06 | R06A | Antihistamines for systemic use | 2512 | 1199 | 74 | 3785 | |
| R05 | Cough and cold preparations | 1162 | 816 | 113 | 2091 | ||
| Rest | R01, R02 (Nasal/throat preparations) | 837 | 439 | 19 | 1295 | ||
| M | Musculo-skeletal system | 6323 (7.1) | 4129 (6.3) | 564 (4.3) | 11,016 (6.6) | ||
| M01 | M01A | NSAIDs | 6192 | 4044 | 555 | 10,791 | |
| Rest | M02, M03, M04, M05 | 131 | 85 | 9 | 225 | ||
| A | Alimentary tract and metabolism | 5864 (6.5) | 2230 (3.4) | 852 (6.4) | 8946 (5.3) | ||
| A02 | Acid-related disorders | 1246 | 1070 | 316 | 2632 | ||
| A03 | Functional gastrointestinal disorders | 1409 | 492 | 289 | 2190 | ||
| A10 | Drugs used in diabetes | 1073 | 9 | 7 | 1089 | ||
| Rest | A01, A04, A06-09, A11, A12 | 2136 | 659 | 240 | 3035 | ||
| D | Dermatologicals | 3587 (4.0) | 2823 (4.3) | 158 (1.2) | 6568 (3.9) | ||
| D06 | Antibiotics/chemotherapeutics | 1561 | 1334 | 56 | 2951 | ||
| D07 | Topical dermatological corticosteroids | 1109 | 1010 | 65 | 2184 | ||
| Rest | D01, D02, D04, D05, D08, D10, D11 | 917 | 479 | 37 | 1433 | ||
| P | Antiparasitic products | 3872 (4.3) | 353 (0.5) | 29 (0.2) | 4254 (2.5) | ||
| P02 | P02C | Antinematodal agents | 3566 | 47 | 4 | 3617 | |
| Rest | P01, P03 | 306 | 306 | 25 | 637 | ||
| C | Cardiovascular system | 3037 (3.4) | 628 (1.0) | 212 (1.6) | 3877 (2.3) | ||
| C05 | C05A | Haemorrhoids and anal fissures | 1162 | 331 | 38 | 1531 | |
| Rest | C01, C02, C03, C05B-C, C07, C08, C09, C10 | 1875 | 297 | 174 | 2246 | ||
| G | Genito-urinary system/sex hormones | 2801 (3.1) | 89 (0.1) | 10 (0.1) | 2900 (1.7) | ||
| G03 | G03A | Hormonal contraceptives systemic | 1949 | 13 | 3 | 1965 | |
| Rest | G01, G02, G03B-H, G04 | 852 | 76 | 7 | 935 | ||
| H | Systemic hormonal preparations | 674 (0.8) | 580 (0.9) | 585 (4.4) | 1839 (1.1) | ||
| H02 | H02A | Corticosteroids (for systemic use) | 403 | 574 | 583 | 1.560 | |
| Rest | H01, H03, H04, H05 | 271 | 6 | 2 | 259 | ||
| Rest | B, L, V | 605 (0.7) | 70 (0.1) | 26 (0.2) | 701 (0.4) | ||
| All | 89,597 (100) | 65,070 (100) | 13,216 (100) | 167,883 (100) | |||
Propulsives (A03F) account for 93.4%.
Antibiotics for topical use (D06A) account for 87.4%.
Blood and blood-forming organs; L: antineoplastic and immunomodulating agents; V: various.
The 10 most frequently prescribed drug types (ATC-code, 3rd level). Proportion (%) of all prescriptions and prescription rate (Pr. rate) for all contacts and per contact type.
| All contacts | % | Pr. rate (95% CI) | Telephone consultations | % | Pr. rate (95% CI) |
|---|---|---|---|---|---|
| Penicillin (J01C) | 36.1 | 9.4 (9.3–9.5) | Penicillin (J01C) | 20.3 | 4.8 (4.7–4.8) |
| Ophtalmological anti-infectives (S01A) | 10.5 | 2.7 (2.7–2.8) | Ophtalmological anti-infectives (S01A) | 15.6 | 3.6 (3.6–3.7) |
| NSAIDs (M01A) | 6.4 | 1.7 (1.6–1.7) | NSAIDs (M01A) | 6.9 | 1.6 (1.6–1.7) |
| Opioids (N02A) | 3.9 | 1.0 (1.0–1.0) | Opioids (N02A) | 4.9 | 1.2 (1.1–1.2) |
| Macrolides and lincosamides (J01F) | 3.8 | 1.0 (1.0–1.0) | Sulfonamides and trimethroprim (J01E) | 4.0 | 0.9 (0.9–1.0) |
| Adrenergics, inhalants (R03A) | 3.0 | 0.8 (0.8–0.8) | Antinematodal agents (P02C) | 4.0 | 0.9 (0.9–1.0) |
| Sulfonamides and trimethroprim (J01E) | 2.6 | 0.7 (0.7–0.7) | Adrenergics, inhalants (R03A) | 3.4 | 0.8 (0.8–0.8) |
| Antihistamines (for systemic use) (R06A) | 2.3 | 0.6 (0.6–0.6) | Antihistamines for systemic use (R06A) | 2.8 | 0.7 (0.6–0.7) |
| Antinematodal agents (P02C) | 2.2 | 0.6 (0.5–0.6) | Antideppresants (N06A) | 2.5 | 0.6 (0.6–0.6) |
| Antibiotics for topical use (D06A) | 1.5 | 0.4 (0.4–0.4) | Hormonal contraceptives for systemic use (G03A) | 2.2 | 0.5 (0.5–0.5) |
| Clinic consultations | Home visits | ||||
| Penicillin (J01C) | 54.3 | 19.6 (19.4–19.8) | Penicillin (J01C) | 53.8 | 8.7 (8.5–8.9) |
| NSAIDs (M01A) | 6.2 | 2.2 (2.2–2.3) | Macrolides and lincosamides (J01F) | 7.7 | 1.2 (1.2–1.3) |
| Macrolides and lincosamides (J01F) | 5.6 | 2.0 (2.0–2.1) | Opioids (N02A) | 5.4 | 0.9 (0.8–0.9) |
| Ophtalmological anti-infectives(S01A) | 5.3 | 1.9 (1.9–2.0) | Corticosteriods for systemic use (H02A) | 4.4 | 0.7 (0.7–0.8) |
| Adrenergic inhalants (R03A) | 2.6 | 0.9 (0.9–1.0) | NSAIDs (M01A) | 4.2 | 0.7 (0.6–0.7) |
| Opioids (N02A) | 2.2 | 0.8 (0.8–0.9) | Adrenergics, inhalants (R03A) | 2.4 | 0.4 (0.3–0.4) |
| Antihistamines for systemic use (R06A) | 1.8 | 0.7 (0.6–0.7) | Drugs for peptic ulcers and GERD (A02B) | 2.3 | 0.4 (0.3–0.4) |
| Antibiotics for topical use (D06A) | 1.8 | 0.7 (0.6–0.7) | Propulsives (A03F) | 2.1 | 0.3 (0.3–0.4) |
| Otologicals (S02A + S02C) | 1.8 | 0.6 (0.6–0.7) | Quinolone antibacterials (J01M) | 2.2 | 0.3 (0.3–0.3) |
| Drugs for peptic ulcers (A02B) | 1.6 | 0.5 (0.5–0.6) | Ophtalmological anti-infectives (S01A) | 1.9 | 0.3 (0.3–0.3) |
Number of prescriptions of a specific drug type per 100 contacts.